Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammation reprograms fibro-adipogenic progenitors to sustain immunopathogenic niches in myositis.

Cell death & disease·2026
Same author

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol.

Neurological research and practice·2026
Same author

Myeloid dendritic cell subsets characterise muscle in patients with inclusion body myositis and correlate with the IFN-γ pathway and effector T cell markers.

Annals of the rheumatic diseases·2026
Same author

Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis.

Acta neuropathologica·2026
Same author

Semi-quantitative analyses of muscle magnetic resonance imaging for pattern recognition in early idiopathic inflammatory myopathies.

Journal of neuromuscular diseases·2026
Same author

Altered network recruitment in multiple sclerosis patients during resting state.

Multiple sclerosis and related disorders·2026
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry
10:58

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Published on: September 27, 2020

5.2K

Neonatal Fc Receptor-Targeted Therapies in Neurology.

Christopher Nelke1, Marianna Spatola2, Christina B Schroeter1

  • 1Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Dusseldorf, Germany.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 8, 2022
PubMed
Summary
This summary is machine-generated.

FcRn-targeted therapies deplete pathogenic immunoglobulin G (IgG) by blocking IgG recycling, offering a promising treatment for autoimmune neurological diseases like myasthenia gravis and others.

Keywords:
AntibodyFcIgGNeurologyTherapy

More Related Videos

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

3.9K
Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery
07:27

Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery

Published on: June 30, 2021

2.2K

Related Experiment Videos

Last Updated: Jul 1, 2026

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry
10:58

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Published on: September 27, 2020

5.2K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

3.9K
Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery
07:27

Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery

Published on: June 30, 2021

2.2K

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Autoantibodies play a significant role in various neurological diseases.
  • Myasthenia gravis is a prime example of an antibody-mediated neurological disorder.
  • Numerous other neurological conditions involving antibodies targeting neuronal or glial antigens have been identified.

Purpose of the Study:

  • To review the mechanisms of FcRn-targeted therapies.
  • To evaluate the therapeutic potential of FcRn blockade for neurological diseases.

Main Methods:

  • FcRn blockade prevents IgG binding to the neonatal Fc receptor (FcRn).
  • This blockade promotes lysosomal degradation of IgG, leading to its depletion.
  • Therapeutic strategies involve enhancing IgG degradation via FcRn-targeted approaches.

Main Results:

  • FcRn blockade effectively depletes IgG, a successful strategy in generalized myasthenia gravis.
  • FcRn-targeted therapies are under investigation for autoimmune encephalopathies, neuromyelitis optica spectrum disorders, and inflammatory neuropathies.

Conclusions:

  • FcRn-targeted therapies represent a powerful approach for treating antibody-mediated neurological diseases.
  • These therapies hold significant potential for managing a range of neurological conditions driven by pathogenic autoantibodies.